ReviewNeuroscience letters2021
Neurological issues during COVID-19: An overview.
Review in Neuroscience letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Interaction of HERVs with PAMPs in Dysregulation of Immune Response Cascade Upon SARS-CoV-2 Infections.International journal of molecular sciences · 2024Review
- Understanding contextual and practical factors to inform WHO recommendations on using chest imaging to monitor COVID-19 pulmonary sequelae: a qualitative study exploring stakeholders' perspective.Health research policy and systems · 2024Article
- Developing a Blood Cell-Based Diagnostic Test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Peripheral Blood Mononuclear Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- SARS-CoV-2 awakens ancient retroviral genes and the expression of proinflammatory HERV-W envelope protein in COVID-19 patients.iScience · 2023Article
- Unravelling Pathophysiology of Neurological and Psychiatric Complications of COVID-19 Using Brain Organoids.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2023Review
- Article
- Article
- Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson's Disease: A Narrative Review.Brain sciences · 2022Review
- SARS-CoV-2 interacts with renin-angiotensin system: impact on the central nervous system in elderly patients.GeroScience · 2022Review
- COVID-19 and the Pediatric Nervous System: Global Collaboration to Meet a Global Need.Neurocritical care · 2021Article
- Anticoronavirus and Immunomodulatory Phenolic Compounds: Opportunities and Pharmacotherapeutic Perspectives.Biomolecules · 2021Review
- MRI negative myelopathy post mild SARS-CoV-2 infection: vasculopathy or inflammatory myelitis?Journal of neurovirology · 2021Article
- Double stranded RNA drives anti-viral innate immune responses, sickness behavior and cognitive dysfunction dependent on dsRNA length, IFNAR1 expression and age.Brain, behavior, and immunity · 2021Article
- Effect of a Brain-Computer Interface Based on Pedaling Motor Imagery on Cortical Excitability and Connectivity.Sensors (Basel, Switzerland) · 2021Article
- Three Cases of Severe ME/CFS in Adults.Healthcare (Basel, Switzerland) · 2021Article
- Viruses and Endogenous Retroviruses as Roots for Neuroinflammation and Neurodegenerative Diseases.Frontiers in neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
COVID-19 has shaken the core of the medical health system. The wide spread death and destruction of patients and health care workers in unprecedented in the modern era. While the pulmonary complications have received the most attention, it is the neurological manifestations that are disabling, persistent and common in patients infected with SARS-CoV-2. The entire neuro-axis can be involved resulting in a wide variety of manifestations. While the pathophysiology is not well understood, many of the clinical manifestations seem to be immune mediated. The socio-economic consequences of these complications are dire. These unprecedented times also calls for unprecedented action. Novel clinical trial designs need to be considered so that multiple agents can be studied. In the context of these clinical trials, disease pathophysiology and standardized batteries and biological markers for patient assessment need to be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.